LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

Overview

The study will evaluate the safety, tolerability and efficacy of LUT014 gel topically administered in breast cancer patients who developed radiation dermatitis. Subjects enrolled to part 1 will be enrolled to receive the study treatment (open label treatment) for 28 days and will be followed up for 2 months after the completion of study treatment. Subject in Part 2 will be randomized in 1:1 ratio to receive either the study drug or placebo (double-blind treatment) for qd topical application for 28 days and will be followed up for 2 months after the completion of study treatment.

Full Title of Study: “A Two-Part (Open-Label Followed by Randomized, Double-Blind, Placebo-Controlled) Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of Topically Administered LUT014 for the Treatment of Radiation-Induced Dermatitis in Breast Cancer Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: June 16, 2022

Interventions

  • Drug: LUT014 Gel
    • Topical application qd for 28 days
  • Drug: Placebo for LUT014 Gel
    • Matching placebo for qd topical application for 28 days

Arms, Groups and Cohorts

  • Experimental: LUT014 Gel
    • LUT014 Gel topical application to the dermatitis area qd for 28 days
  • Placebo Comparator: Placebo for LUT014 Gel

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 1 subjects)
    • Time Frame: 12 weeks (83 days)
    • Common Terminology Criteria for Adverse Events Version 5.0
  • Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire (Part 2 subjects)
    • Time Frame: 14 Days
    • Dermatology Life Quality Index questionnaire

Secondary Measures

  • Change in the severity of radiation dermatitis assessed by CTCAE (Part 1 subjects)
    • Time Frame: 12 weeks (83 days)
    • CTCAE grading scale for dermatitis radiation
  • Change in the severity of radiation dermatitis assessed by RTOG/EORTC (part 1 subjects)
    • Time Frame: 12 weeks (83 days)
    • Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
  • Change in the severity of radiation dermatitis based on self reporting Dermatology QoL questionnaire
    • Time Frame: 12 weeks (83 days)
    • Dermatology Life Quality Index questionnaire (part 1 subjects)
  • Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE (Part 2 subjects)
    • Time Frame: 12 weeks (83 days)
    • CTCAE grading scale for dermatitis radiation

Participating in This Clinical Trial

Inclusion Criteria

1. Female subjects diagnosed with stage Tis, T0-T3, N0-N2, M0 Breast Cancer; 2. Subject is ≥18 years at the time of signing the informed consent form (ICF); 3. Radiation dermatitis of Grade 2, based on the NCI CTCAE at the Screening and Baseline (D0) visits; 4. Completed fractionated radiation therapy for breast prior to first dose of study drug (Day 0); 5. A score of ≥ 6 reported in the Dermatology Life Quality Index at the Screening and Baseline Visits; 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 7. Females of child-bearing potential must have a negative pregnancy test at screening and must agree to use an effective contraception method* or abstain from sex throughout the study until Day 83; 8. Expected life expectancy greater than 6 months Exclusion Criteria:

1. Bilateral breast irradiation; 2. Planned internal mammary node irradiation with electrons. Planned photon coverage of internal mammary chain nodes is acceptable for inclusion in this study; 3. Planned partial breast accelerated irradiation; 4. Any cutaneous infection or significant skin disease at Screening or Baseline (Day 0) other than the dermatitis in the area(s) irradiated during fractionated radiation therapy; 5. T4 breast cancer or direct skin involvement by breast cancer; 6. Breast implants or underwent breast reconstruction; 7. Any cancer other than breast cancer within 3 years of Screening, except for carcinoma in situ of the cervix; 8. Pregnant or lactating; 9. History of active systemic lupus erythematosus or scleroderma that is believed to increase the risk of developing radiation-induced dermatitis or its severity; 10. Clinically significant co-morbid diseases 11. Treatment with a serine/threonine-protein kinase B-Raf (B-Raf) inhibitor, including but not limited to Zelboraf® (vemurafenib), Tafinlar® (dabrafenib), Braftovi® (encorafenib), and Nexavar® (sorafenib), within 30 days or 5 half-lives of the drug prior to Screening, whichever is longer; 12. Treatment with a topical corticosteroid o the irradiated chest area within 14 days prior to Baseline (Day 0). 13. Treatment with a systemic corticosteroid within 14 days prior to Baseline (Day 0), except for low dose systemic corticosteroids (e.g., 8-20 mg dexamethasone or comparable) given for up to one or two days every two weeks as part of standard of care for the prevention or treatment of chemotherapy-induced nausea and vomiting (CINV); 14. Treatment with any investigational drug within 30 days or 5 half-lives of drug prior to Screening, whichever is longer; 15. Known hypersensitivity to any of the inactive ingredients of the study drug.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Lutris Pharma Ltd.
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.